Clinical trial
Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes
NCT00048100 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00048100 |
|---|---|
| Title | Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes |
| Official title | Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes for Therapy of Relapsed Leukemia After Allogeneic Stem Cell Therapy |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Myelocytic, Acute |
| Intervention type | Biological, Procedure |
| Interventions | Apheresis, Stem Cell Transplant |
| Enrollment | 2 |
| Start date | Feb 1, 2001 |
| Primary completion | May 1, 2005 |
| Completion | May 1, 2005 |
| First posted | Oct 25, 2002 |
| Last update posted | Oct 31, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: